These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 6771095

  • 1. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men.
    Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J.
    Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095
    [Abstract] [Full Text] [Related]

  • 2. Use of low-dosage oral cyproterone acetate as a male contraceptive.
    Wang C, Yeung KK.
    Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
    [Abstract] [Full Text] [Related]

  • 3. The influence of pharmaceutical compounds on male fertility.
    Neumann F, Diallo FA, Hasan SH, Schenck B, Traore I.
    Andrologia; 1976 Mar; 8(3):203-35. PubMed ID: 793446
    [Abstract] [Full Text] [Related]

  • 4. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
    Soufir JC, Jouannet P, Marson J, Soumah A.
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF, Rollet J.
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [Abstract] [Full Text] [Related]

  • 6. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC, Bremner WJ, Costantino A, Di Cintio G, Flamigni C.
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [Abstract] [Full Text] [Related]

  • 7. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 8. The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme.
    Bain J, Rachlis V, Robert E, Khait Z.
    Contraception; 1980 Apr; 21(4):365-79. PubMed ID: 6771093
    [Abstract] [Full Text] [Related]

  • 9. Effect of cyproterone acetate (CPA) on gonadal and adrenal function in men.
    de la Torre B, Norén S, Hedman M, Diczfalusy E.
    Contraception; 1979 Oct; 20(4):377-96. PubMed ID: 228907
    [Abstract] [Full Text] [Related]

  • 10. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM, Gow SM, Wu FC.
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [Abstract] [Full Text] [Related]

  • 11. Pituitary and ovarian responsiveness to a graded gonadotropin releasing factor stimulation test in women using a low-estrogen or a regular type of oral contraceptive.
    Spellacy WN, Kalra PS, Buhi WC, Birk SA.
    Am J Obstet Gynecol; 1980 May 01; 137(1):109-15. PubMed ID: 6768295
    [Abstract] [Full Text] [Related]

  • 12. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov 01; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 13. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L, Galbignani E.
    Contraception; 1990 Dec 01; 42(6):611-9. PubMed ID: 2150631
    [Abstract] [Full Text] [Related]

  • 14. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM, Nashan D, Hubert W, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Jan 01; 74(1):84-90. PubMed ID: 1727833
    [Abstract] [Full Text] [Related]

  • 15. Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers.
    Koch UJ, Lorenz F, Danehl K, Ericsson R, Hasan SH, Keyserlingk DV, Lübke K, Mehring M, Römmler A, Schwartz U, Hammerstein J.
    Contraception; 1976 Aug 01; 14(2):117-35. PubMed ID: 949890
    [Abstract] [Full Text] [Related]

  • 16. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug 01; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

  • 17. Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human.
    Kumari GI, Das RP, Madoiya KK, Jain AK, Roy S.
    Fertil Steril; 1977 Nov 01; 28(11):1168-74. PubMed ID: 562781
    [Abstract] [Full Text] [Related]

  • 18. An examination of blood steroid and gonadotropin concentrations in relation to fertility status and testicular function in men.
    Pierrepoint CG, Jenkins BM, Wilson DW, Phillips MJ, Gow JG.
    Fertil Steril; 1982 Oct 01; 38(4):465-70. PubMed ID: 6811340
    [Abstract] [Full Text] [Related]

  • 19. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
    Foegh M, Nicol K, Petersen IB, Schou G.
    Contraception; 1980 Jun 01; 21(6):631-40. PubMed ID: 6775869
    [Abstract] [Full Text] [Related]

  • 20. Endocrinology of male infertility.
    de Kretser DM.
    Br Med Bull; 1979 May 01; 35(2):187-92. PubMed ID: 387166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.